<DOC>
	<DOCNO>NCT01980407</DOCNO>
	<brief_summary>In China , S-1 novel oral fluoropyrimidine demonstrate high efficacy gastrointestinal cancer . The new regimen oxaliplatin leucovorin expect achieve encourage efficacy gastric cancer . This study aim evaluate feasibility SOL regimen efficacy tolerability Chinese patient advance gastric cancer .</brief_summary>
	<brief_title>Feasibility Study SOL ( S-1 , Oral Leucovorin , Oxaliplatin ) Patients With Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<criteria>Age 18 year old Histologically cytologically document gastric adenocarcinoma Performance status ( ECOG scale ) : 02 Life expectancy ≥ 3 month No previous treatment ( include : radiotherapy , chemotherapy immunotherapy ) Prior systemic therapy ( instance , cytotoxic chemotherapy active/passive immunotherapy ) adjuvant neoadjuvant treatment nonmetastatic ( M0 ) disease complete within 6 month prior initiation study treatment . WIth Measurable Target lesion Patients sign write informed consent study entry History hypersensitivity fluoropyrimidines , S1 , oxaliplatin ingredient product Inadequate hematopoietic function : WBC≦5,000/mm3 ; ANC≦2,000/mm3 ; Platelet≦100,000/mm3 Inadequate organ function define : Total bilirubin &gt; 2 pper limit normal range ( ULN ) ; ALT / AST &gt; 2.5 upper limit normal range ( ULN ) ( &gt; 5.0 x ULN hepatic metastasis ) ; serum creatinine &gt; 2 upper limit normal range ( ULN ) ; Symptomatic peripheral neuropathy ≥ NCI CTC AE grade 1 ; Receiving concomitant treatment fluoropyrimidines fluorocytosine ; Pregnancy lactation woman , woman suspect pregnancy men unless use reliable appropriate contraceptive method ; Mental status fit chemotherapy therapy presence serious concomitant illness might aggravate study medication ; History ventricular arrhythmia congestive heart failure ; Active cardiac disease e.g . decompensate myocardial infarction within 6month period precede entry study ; Significant comorbid medical condition , include , limited , Chronic obstructive pulmonary disease , interstitial pneumonia , pulmonary heart failure , renal failure , hepatic failure , haemorrhagic peptic ulcer , mechanical , paralytic poor control diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>S-1</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>